A pilot randomised controlled trial of abrupt versus gradual smoking cessation in combination with vaporised nicotine products for people receiving alcohol and other drug treatment.

Plain-language guide to PMID 35405479 (2022): pilot randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 35405479
Journal: Addictive behaviors
Year: 2022
Study type: Randomized Controlled Trial
Authors: Skelton E et al. (10 authors)
DOI: 10.1016/j.addbeh.2022.107328

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

This is the first study to examine combining the use of a VNP with a gradual or abrupt cessation guideline.

This study aims to test the potential feasibility of a quit smoking strategy (abrupt verses gradual cessation) in combination with vaporised nicotine products among people in AOD treatment.

Why It Was Studied

Vaporised nicotine products (VNPs) may be a potential quit smoking strategy.

Most research has permitted participants to use VNPs ad libitum.

Who Took Part

Participants were recruited from AOD programs located within one area health service in Australia.

Feasibility was assessed through successful recruitment rates, retention, and adherence to study conditions.

How the Study Was Run

In design terms this was a randomized and pilot study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

The researchers conducted a pilot randomised controlled trial between April 2018 and July 2019.

Participant perceived helpfulness and satisfaction assessed acceptability.

What Was Measured

The subject headings attached to it are Electronic Nicotine Delivery Systems, Ethanol, Nicotine, Pilot Projects, Smoking Cessation and Tobacco Use Cessation Devices.

The authors tagged it with the keywords E-cigarette, Nicotine dependence, Quit strategy and Vaporised nicotine product.

What This Means in Plain Language

The paper is a randomized and pilot study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Addictive behaviors), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.